Duke logo

BLU-285-1303 for Advanced GIST - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if a drug called avapritinib (BLU-285) will work against GIST.

What is the Condition Being Studied?

Locally advanced or advanced GIST (Gastrointestinal stromal tumor)

Who Can Participate in the Study?

Adults with GIST tumor who:

- Are locally advanced, but cannot be removed by surgery

OR

- Advanced (spread throughout the body)

Disease has gotten worse on prior therapies with drugs called tyorisine kinase inhibitors (no more than 3 kinds)

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Be randomized (like the flip of a coin) to take either avapritinib or regoarafenib by the mouth every day.
- Have study visits once a month at Duke

Study Details

Full Title
An International, Multicenter, Open-Label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Principal Investigator
Jennifer Choe
Protocol Number
IRB:PRO00091857
NCT:NCT03465722
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698